The Office of the Vice President for Research has scheduled 2 sessions to introduce the eProtocol system to the research community. The eProtocol system is a web-based platform for IACUC and IBC protocols.
All sessions will be hosted by Dr. Lynn M. Veatch, current site administrator for the eProtocol system and will include representation from the IACUC and IBC. Attendance is open to all and highly recommended for primary personnel working in the system.
In order to know if additional sessions are needed, please drop an email to Dr. Veatch (email@example.com) letting her know the sessions you plan to attend.
Please take this opportunity to learn about this exciting enhancement to our research toolkit.
Then you should know that MUSC has adopted a new campus policy for the review and approval of human pluripotent stem cell research. The “MUSC Research Using Human Stem Cells Policy” will take effect on July 1, 2017. In order to be compliant, MUSC leadership has charged a new oversight body, the Stem Cell Research Oversight (SCRO) committee, with oversight responsibilities for all research projects that fall under this policy.
Applicability and Scope of Oversight of the SCRO Policy
The scope of the MUSC Research Using Human Stem Cells Policy is limited to a well-defined subset of life sciences research that involves the storage of human embryonic stem cells and the derivation or use of all types of human pluripotent stem cells at MUSC. The aim of this policy is to help ensure that such research is conducted with the highest ethical and scientific research standards, and in compliance with all applicable federal and state regulations, MUSC policies, and the requirements of extramural research sponsors. Non-compliance with this Policy may result in suspension, limitation, or termination of Federal research funding.
Principal Investigator Responsibilities
It is the responsibility of the Principal Investigator to identify research involving the derivation or use of human pluripotent stem cells and notify the SCRO for review.
SCRO Notification of Research with Human Stem Cells
The formal SCRO review starts with the PI submission of a SCRO registration form. Instructions for submitting this form are available on the SCRO website. The SCRO will review the application and determine whether or not the project indeed falls into the scope of human stem cell research oversight. All individuals involved in this scope of research will be required to complete the SCRO training module in the online CITI Human Stem Cell program.
Researchers with questions are encouraged to talk to the SCRO Program Manager (Dr. Yashmin Karten, 843-792-6521, firstname.lastname@example.org).
MUSC website on SCRO
MUSC Research Using Human Stem Cells Policy
National Academies of Sciences Guidelines
NIH Guidelines on Human Stem Cell Research
NIH Human Embryonic Stem Cell Registry
International Society for Stem Cell Research
To the MUSC Research Community:
On behalf of Vice President for Research, Dr. Kathleen Brady, we are pleased to announce the creation of a new online MUSC Research Events Calendar available to our community.
The Research Calendar provides a one-stop shop to view research events that are open to the MUSC community and external public audiences. The calendar provides views by date or by calendar month, and has a tab for viewing clinical trials for recruitment that are not typically bounded by date ranges. Public audiences can view events by going to the research homepage research.musc.edu and click on Upcoming MUSC Research Events.
Many thanks to Kristi Adams, Carla Frichtel, and Teresa Kelechi for this support of this endeavor!
Loretta Lynch-Reichert, M.S.
Director, Office of Strategic Initiatives and Policy Management
Office of the Provost
Medical University of South Carolina
Effective February 9, 2017, if the recipient organization has submitted a renewal application on or before the date by which a Final Research Performance Progress Report (Final-RPPR) would be required for the current competitive segment, then submission of an "Interim-RPPR" via eRA Commons is now required. Based on this requirement, the NIH will discontinue the policy for renewal applications whereby, “whether funded or not,” the progress report contained in the renewal application may serve in lieu of a separate final progress report.
An Interim-RPPR link for the grant will appear in the Status tab in eRA Commons after the period of performance end date has passed. In the event that the renewal application is funded, NIH will treat the Interim-RPPR as the annual performance report for the final year of the previous competitive segment. If the renewal application is not funded, the Interim-RPPR will be treated by NIH staff as the institution's Final-RPPR.
As stated in NOT-OD-17-022, the Interim-RPPR must be submitted via the eRA Commons no later than 120 calendar days from the period of performance end date. If a recipient fails to comply with this reporting requirement, NIH may take one or more enforcement actions, such as a decision to withhold a non-competing continuation award, consistent with NIHGPS Chapter 8.5.2. NIH will maintain the business rule in the RPPR module enabling institutional signing officials (SOs), at their discretion, to delegate submission of the Final RPPR or Interim-RPPR to the Program Director/Principal Investigator (PD/PI).
Further guidance is provided through the scenarios below outlining the process of when to submit a Final or Interim-RPPR.
Status of Competing Renewal Application
Competing Renewal not submitted
Submit a Final-RPPR no later than 120 calendar days from the period of performance end date.
Competing Renewal submitted
Submit an Interim-RPPR no later than 120 calendar days from the period of performance end date. If the competing renewal is funded, NIH will treat the Interim-RPPR as the annual performance report for the final year of the previous competitive segment.
Competing Renewal submitted but not funded
Submit an Interim-RPPR no later than 120 calendar days from the period of performance end date. If the competing renewal is not funded, NIH will treat the Interim-RPPR as the institution's Final-RPPR. To reduce burden NIH will not require recipients to submit an additional Final-RPPR if the renewal application is not funded.
Reminder: Effective January 2017, NIH requires recipients to report on Project Outcomes in Section I of the Interim and Final-RPPR. Therefore, in each scenario listed above, Project Outcomes must be provided by the recipient in order for the recipient to submit their final report in eRA Commons. Otherwise, eRA Commons will not allow recipients to submit the required report and recipients will be considered non-compliant.
NOTE: Implementation of the Final RPPR for Small Business Innovation and Research (SBIR) and Small Business Technology Transfer (STTR) grants will occur approximately 2 months after implementation for all other NIH grants due to unique final reporting requirements under the Small Business Administration's SBIR/STTR Policy Directive.
Phase-0 Program Solicitation Detailed Information and Guidelines
How to Find Research Funding Opportunities at MUSC?
Grant Forward Database is a comprehensive database is available for MUSC faculty, postdocs, staff and students.
You can access Grant Forward at http://www.grantforward.com. To use the full search features, including saved searches and personalized grant recommendations, you may create an account using your musc.edu email address. We also encourage you to create your "Researcher Profile" to start receiving grant recommendations in your inbox. Select how often you would like to receive these messages - daily, weekly, monthly.
For tips on getting started in Grant Forward and training information on using the database, go to https://www.grantforward.com/support.
For questions about the MUSC Funding Portal or assistance with navigating the many online resources to identify funding opportunities, please contact email@example.com.
NIH Notice NOT-OD-17-033 announces how Inauguration Day will affect deadlines that fall on Friday, January 20, as that is considered a Federal holiday for most NIH staff.
Please be aware and plan accordingly as NIH will have limited staffing on this date.
Impact on Support
• eRA Service Desk - open with reduced staffing
• General Grants Information support desk - unavailable
• Institute/Center staff - unavailable
Impact on Due Dates
• All application due dates that fall on January 20, 2017 will move to January 23, 2017, including (but not limited to) due dates for the following funding opportunity announcements:
o PAR-15-068 - NIDDK Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34)
o RFA-CA-16-502 - Limited Competition: The Chernobyl Tissue Bank - Coordinating Center (U24)
Impact on Systems
• All eRA systems will remain operational
Please share this information with everyone (faculty, students/postdocs and staff) involved with grant proposal submissions or grant awards administration in your areas.
Should anyone have questions, please contact your assigned ORSP Grant Administrator or call 843-792-3838 for assistance.
NIH Notice NOT-OD-17-030 updates the NIH/AHRQ font guidance for applications due on or after January 25, 2017.
The Notice updates NIH’s recommended font list. Please note that NIH no longer requires that black text be used within grant application attachments.
For applications submitted for due dates on or after January 25, 2017, text in PDF attachments must follow these minimum requirements:
Since some PDF converters may reduce font size, it is important to confirm that the final PDF document complies with the font requirements.
The following fonts are recommended, although other fonts (both serif and non-serif) are acceptable if they meet the above requirements.
Legibility is of paramount importance. Applications that include PDF attachments that do not conform to the minimum requirements listed above may be withdrawn from consideration.
NIH Notice NOT-OD-17-022 announced NIH’s implementation of Final Research Performance Progress Reports (Final RPPR or F-RPPR) effective January 1, 2017.
The Final RPPR will replace the Final Progress Report (FPR) and will be submitted via a new eRA Commons module.
A significant change with implementation of the F-RPPR is that in order to maximize public transparency, NIH will not maintain the current Type 2 policy which in accordance with NIHGPS Chapter 8.6.2 states that "whether funded or not" the progress report contained in the Type 2 application may serve in lieu of a separate final progress report.
NIH will request that organizations submit an "Interim-RPPR" while their renewal application (Type 2) is under consideration. In the event that the Type 2 is funded, NIH will treat the Interim-RPPR as the annual performance report for the final year of the previous competitive segment. If the Type 2 is not funded, the Interim-RPPR will be treated by NIH staff as the institution's Final-RPPR.
NIH is aligning its reporting requirement with other Federal research agencies and therefore will not be making any changes to the deadline for submitting the final report- i.e., the Final RPPR or Interim-RPPR must be submitted via eRA Commons no later than 120 calendar days from the period of performance end date. If a recipient fails to comply with this reporting requirement, NIH may take one or more enforcement actions, such as a decision not to make a non-competing continuation award, consistent with NIHGPS Chapter 8.5.2. NIH also plans to maintain the business rule in the RPPR module enabling institutional signing officials (SOs), at their discretion, to delegate submission of the Final RPPR or Interim-RPPR to the Program Director/Principal Investigator (PD/PI).
Note: Implementation of the Final RPPR for Small Business Innovation and Research (SBIR) and Small Business Technology Transfer (STTR) grants will occur approximately 2 months after implementation for all other NIH grants due to unique final reporting requirements under the Small Business Administration's SBIR/STTR Policy Directive.
FAQs and additional information pertaining to NIH's implementation of the F-RPPR will be available on the NIH RPPR website.
DLAR has modified our template for our notices regarding moribund animals. Previously, when an animal was found in a moribund state, there was an email generated to the laboratory followed by a phone call. Since the animal care program is expected to continue to expand, we are no longer following up with a phone call.
Questions: Suzanne Craig, Director DLAR